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a  b  s  t  r  a  c  t
The  seven-valent  pneumococcal  conjugate  vaccine  (PCV7)  has  been  introduced  in  most  high-income
countries,  although  with  differences  in  age,  timing  and  number  of  primary  doses  before  6 months  of  age
and presence  and  timing  of  a booster  vaccination.  The  objective  was  to  determine  and compare  the  IgG
antibody  levels  and  functionality  of  IgG  responses  (avidity  and  opsonophagocytoses)  at 1 and  2  years  of
age  following  2 primary  doses  with  a  booster  at 11  or 24  months  of  age.
Children  received  PCV7  at  2  and  4  months  (2-dose  group),  or at 2, 4  and  11  months  (2 + 1-dose  group),
or  no PCV7  (controls)  before  1  year  of  age.  All  children  received  a  PCV7  dose  at 24 months  of  age.
At  the  age  of 12  months,  the  2 +  1-dose  group  had  higher  IgG levels  and  functional  antibody  levels,
compared  to the  2-dose  group  for all  serotypes,  but  at  25  months  the  difference  between  the  2-dose  and
2  +  1-dose  groups  had  disappeared  for  most  serotypes.  The  kinetics  of  opsonophagocytic  antibodies  were
in  line  with  the  speciﬁc  IgG  antibody  levels  for  most  serotypes,  although  differences  between  the  2-dose
and the  2  +  1-dose  group  were  more  pronounced  in  OPA  activity  as  compared  to  the IgG  levels  especially
at the  age  of 24  months.Delaying  the  booster  dose  from  11  months  to  24  months  after  2 primary  doses  resulted  in  signiﬁcantly
higher  OPA  GMTs  one  month  after  the  booster  dose.  This  must,  however,  be  balanced  against  the risk  of
leaving  children  unboosted  between  the  age  of 11  and  24  months  at  a  time  when  disease  risk  is  still  high.
Local  decisions  about  the timing  of  a booster  dose  should  also  take  into  account  vaccine  coverage  and
the indirect  herd  effect  in  a  well  vaccinated  population.
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. IntroductionStreptococcus pneumoniae is a main cause of serious bacte-
ial infections in children in the ﬁrst years of life with clinical
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syndromes varying from mucosal disease (pneumonia, otitis
media) to invasive pneumococcal disease (IPD; sepsis, bacteremia
and meningitis) [1,2]. Pneumococcal conjugate vaccines provide
protection in infants against vaccine serotype pneumococcal dis-
ease [3,4]. The 7-valent pneumococcal conjugate vaccine (PCV7)
contains serotypes 4, 6B, 9V, 14, 18C, 19F and 23F conjugated to
CRM197 and was  indicated for use in a 3 + 1 schedule [5], though
recently the WHO  has recommended a 2 + 1 or 3 + 0 schedule as
alternative schedules [6]. At present, more than half of the Euro-
pean countries have introduced PCVs in a reduced-dose schedule
with 2 primary doses and a booster dose in the second year of life
[7,8] with surveillance reports conﬁrming high clinical protection
Open access under CC BY-NC-ND license. by these reduced dose schedules [9]. Dagan et al. showed com-
parable protection and carriage rates after the booster dose in a
2 + 1-dose schedule and a 3 + 1-dose schedule [10]. In Australia,
a 3 + 0 PCV7 dose schedule without a booster dose resulted in a
icense. 
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igh vaccine effectiveness (VE) which is similar to VE reported by
ountries where a booster dose is given, questioning the necessity
f a booster vaccination [11]. Also, studies in South Africa conﬁrm
rotection after 3 primary doses without a booster dose [12]. Even
 primary schedule of 2 doses without a booster dose was shown
o equally reduce vaccine serotype carriage at 2 years of age [13].
 systematic review was performed by Scott et al., which showed
hat both a 2- and 3-dose primary series results in seropositivity;
he clinical relevance of the differences found in immunological
esponses is not known [14]. Quantitative serotype-speciﬁc anti-
apsular polysaccharide IgG antibody levels ≥0.35 g/ml after the
rimary series are considered to correlate with protection and have
een used for licensure of PCV7 and PCV13 [15]. For licensure of
CV10 IgG antibody levels after the primary series of ≥0.20 g/ml,
easured in an ELISA with 22F inhibition, was used [16,17]. Besides
he amount of antibodies after vaccination also the quality of these
ntibodies is important. The avidity of antibodies is a quality mea-
urement which deﬁnes the afﬁnity of antibodies for a particular
ntigen [18]. An increased avidity might be related to a more effec-
ive antibody function [19]. Another functional measurement of
neumococcal speciﬁc antibodies is its opsonophagocytic activity.
he primary mechanism for anti-capsular immunity in the host is
hagocytosis, through opsonisation by anticapsular antibodies and
ctivation of complement [20]. Functional antibody levels, mea-
ured as opsonophagocytic activity, provide valuable additional
nformation for serotype-speciﬁc differences in protection [21].
herefore, the WHO  has suggested that in vitro opsonophagocytic
ctivity (OPA) of serum is of added value in the evaluation of PCV
fﬁcacy [15,22].
The aim of this study was to measure the effect of the tim-
ng of the booster dose after 2 primary doses of PCV7 at either
1 or 24 months of age, by determining the IgG levels and lev-
ls of functional antibodies (avidity and opsonophagocytic activity)
nd to evaluate the added value of these functional antibody
evels.
. Materials and methods
.1. Study designs
Between July 2005 and February 2006, before nationwide imple-
entation of PCV7 in the Netherlands (June 2006), 1005 infants
ere enrolled in a randomized controlled trial investigating the
ffects of reduced-dose PCV7 schedules on pneumococcal carriage
uring the ﬁrst two years of life (NCT00189020) [13]. Randomized
roups of infants received various vaccination schedules: two pri-
ary doses of PCV7 at 2 and 4 months of age (2-dose group), two
rimary doses at 2 and 4 months of age followed by a booster dose at
1 months of age (2 + 1-dose group) or no PCV7 vaccination (control
roup). At 24 months of age, an additional or ﬁrst PCV7 vaccina-
ion was offered to all study participants. From this trial, subsets
f infants were included in the immunogenicity arm of the study
n a voluntary basis. Blood samples of 3 ml  were collected at 12
nd 24 months of age and 28–42 days after PCV7 vaccination at
he age of 24 months. Enrolment in this study is shown in Fig. 1.
aseline characteristics (gender, age at primary doses administra-
ion) of the participants were comparable for the different groups
13].
Informed consent was obtained from the parents or guardians of
ll study participants after the nature and possible consequences of
he studies had been fully explained. The study was approved by a
ational medical ethics committee and undertaken in accordance
ith Good Clinical Practice, which includes the provisions of the
eclaration of Helsinki of 1989. Laboratory personnel performing
nalyses were unaware of treatment allocation. 31 (2013) 5834– 5842 5835
2.2. Study vaccines
The licensed 7-valent CRM197-conjugated pneumococcal vac-
cine (PrevenarTM Pﬁzer/Wyeth) was  administered to children in
their ﬁrst year of life during regular well baby-clinic visits, together
with routine DTaP-IPV-Hib immunizations (Pediacel® or Infanrix®)
at 2, 4 and 11 months according to the NIP at that time [23]. PCV7
vaccinations at 24 months of age were administered during a home
visit by trained medical staff.
2.3. Laboratory measurements
After blood collection, serum was  separated and stored at
−20 ◦C until analysis. Serum IgG antibody levels to the 7 vac-
cine pneumococcal capsular polysaccharides 4, 6B, 9V, 14, 18C,
19F and 23F were measured with ELISA using double adsorp-
tion with cell wall polysaccharide and 22F polysaccharide [24].
Subjects with serum IgG geometric mean concentrations (GMC)
≥0.35 g/ml were considered responders. The antibody avidity to
capsular polysaccharides was  measured for serotypes 4, 6B, 14
and 19F at all time-points of a random selection of blood sam-
ples with serotype speciﬁc IgG levels of ≥0.25 g/ml (numbers are
shown in Fig. 1). All serum samples were adapted to an antibody
concentration of 0.25 g/ml. Ammonium thiocyanate was used to
dissociate low-avidity antigen–antibody binding, at least 5 differ-
ent concentrations were tested per sample [25]. Antibody avidity
was  expressed as geometric mean avidity index (GMAI), corre-
sponding to the molar concentration of ammonium thiocyanate
required to produce a 50% reduction in optical density.
Opsonophagocytic activity was determined for all 7 vaccine
serotypes by a 4-fold multiplex opsonophagocytosis assay (OPA)
[26] in a random selection of the serum samples (numbers are
shown in Fig. 1). OPA titers were expressed as serum dilutions with
50% killing of the given serotype. Serum samples with a titer below
the detection limit of 8 were reported as 4 for the purpose of data
analyses.
2.4. Statistical analysis
Results of IgG antibody levels were expressed in GMCs,
avidity indices in geometric mean avidity indices (GMAI) and
opsonophagocytic antibody levels as OPA titers in geometric mean
titers (GMT), all with 95% conﬁdence intervals (CIs). Statistical dif-
ferences in IgG GMC  values, avidity GMAI values and OPA GMT
values were assessed by log transformed unpaired t tests. Propor-
tion responders were tested with 2. Correlations were assessed by
Spearman correlation. All reported p-values are 2-sided, p-values
0.05 were considered signiﬁcant. Comparison between OPA titers
and IgG levels was  performed on the same subset. Analyses were
performed with SPSS 19.0 and GraphPad Prism6.
3. Results
3.1. IgG antibody levels after different vaccination schedules
Levels of IgG antibodies were determined in approximately 80
children per group, except for the control group at 12 months,
which included 28 subjects (Fig. 1).
The results of the 2 + 1-dose and the 2-dose group at the age of 12
months have been described previously by Rodenburg et al. [27]. In
short, the 2 + 1-dose group had signiﬁcantly higher IgG GMCs for all
serotypes one month after the booster dose compared to children
of the 2-dose group, without a booster dose (Table 1). Children in
the control group had signiﬁcantly lower IgG levels for all serotypes
and therefore a lower proportion responders as compared to both
vaccinated groups.
5836 E. van Westen et al. / Vaccine 31 (2013) 5834– 5842
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At 24 months, IgG GMCs of the 2 + 1-dose group had decreased
igniﬁcantly compared to the levels at 12 months. Only 2
ut of 7 serotypes (serotypes 4 and 18C) were still signiﬁ-
antly higher in the 2 + 1-dose group compared with the 2-dose
roup. All vaccinated children still had signiﬁcantly higher IgG
evels for all serotypes compared to controls, but IgG levels
gainst 4 out of 7 serotypes had increased signiﬁcantly at 24
onths compared to 12 months of age in the control group
Table 1).
At 25 months, 1 month after the (re)vaccination of all chil-
ren at 24 months, IgG levels had increased signiﬁcantly for all
hree groups and all serotypes. For serotypes 4 and 9V, IgG lev-
ls in the 2-dose group were signiﬁcantly higher compared to
he 2 + 1-dose group whereas similar levels were found for other
erotypes. Both vaccinated groups had signiﬁcantly higher IgG lev-
ls compared to children of the control group with a ﬁrst PCV7
accination at 24 months, except for serotype 18C. The proportion
esponders at 25 months of age varied between 63% and 99% for
he control group and between 96% and 100% for the 2 and 2 + 1
roup.
IgG GMCs of the 2-dose group at 25 months of age, one month
fter the 24-month- booster dose, were signiﬁcantly higher com-
ared to the 2 + 1-dose group at 12 months of age, one month after
he 11-month booster, for all 7 serotypes. trial, performed before introduction of PCV7 in the Dutch NIP.
3.2. Avidity indices after different vaccination schedules
Avidity indices (AI) were determined in a random subset of the
samples with IgG concentrations ≥0.25 g/ml. The number of sub-
jects varied per group depending on the serotype. At the age of
12 months, numbers of children in the unvaccinated control group
reaching IgG levels of ≥0.25 g/ml were small and were therefore
excluded from analyses. In the 2 + 1-dose group, GMAI of serotype
19F was  signiﬁcantly higher at 12 months compared to the 2-dose
group, but otherwise the avidity was not signiﬁcantly different
(Fig. 2).
At 24 months, a signiﬁcant difference between the 2-dose and
the 2 + 1-dose group was found for serotype 6B, with higher avidity
for the 2 + 1-dose group. Both vaccinated groups had signiﬁcantly
higher GMAIs for serotypes 4 and 6B compared to controls, for the
2 + 1-dose group serotype 19F was also signiﬁcantly higher than in
the controls.
At 25 months, GMAIs were comparable for the 2-dose and
the 2 + 1-dose group. Both vaccinated groups showed signiﬁcantly
higher GMAIs compared to controls for all 4 serotypes.
GMAIs were signiﬁcantly higher for serotype 4 for the 2-dose
group compared with the 2 + 1-dose group one month after the
booster dose, which is at the age of 12 months for the 2 + 1-dose
group and at the age of 25 months for the 2-dose group.
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Table 1
Pneumococcal serotype-speciﬁc IgG antibody levels (GMCs; g/ml) and proportions of children reaching seroprotective levels of ≥0.35 g/ml with 95% CIs in infants after a 2-dose, 2 + 1-dose or no vaccination schedule until 24
months  (controls) at the age of 12 and 24 months, and at 25 months after an additional booster dose (n varied between 71 and 80 subjects per group, except 12 months controls with n = 28).
12 Months 24 Months 25 Months
Controls 2-Dose 2 + 1-Dose Controls 2-Dose 2 + 1-Dose Controls 2-Dose 2 + 1-Dose
Serotype 4
IgG GMC 0.05 (0.03–0.07) 0.28 (0.23–0.34)*,** 2.66 (2.26–3.13)*** 0.10 (0.08–0.12) 0.17 (0.14–0.22)*,** 0.26 (0.22–0.30)*** 2.52 (2.10–3.03) 5.82 (4.87–6.95)*,** 3.83 (3.15–4.66)***
% IgG ≥0.35 g/ml 0 (–) 30 (20–40)*,** 100 (–)*** 8 (2–14) 19 (10–27)*,** 31 (21–42)*** 99 (96–100) 100 (−) 100 (−)
Serotype 6B
IgG GMC 0.07 (0.05–0.10) 0.23 (0.8–0.30)*,** 2.26 (1.63–3.13)*** 0.24 (0.20–0.29) 0.79 (0.56–1.11)** 1.09 (0.80–1.49)*** 0.57 (0.44–0.75) 6.48 (4.73–8.89)** 8.41 (6.20–11.41)***
% IgG ≥0.35 g/ml 4 (0–10) 26 (17–36)*,** 89 (82–96)*** 25 (15–34) 66 (60–77)** 84 (75–92)*** 66 (60–77) 96 (92–100)** 97 (93–100)***
Serotype 9V
IgG GMC 0.05 (0.04–0.07) 0.27 (0.22–0.33)*,** 2.21 (1.89–2.59)*** 0.14 (0.11–0.18) 0.26 (0.19–0.34)** 0.30 (0.24–0.37)*** 1.80 (1.50–2.15) 4.25 (3.64–4.96)*,** 3.15 (2.63–3.76)***
% IgG ≥0.35 g/ml 0 (–) 35 (25–46)*,** 100 (–)*** 18 (10–27) 34 (23–44)** 31 (21–42)*** 98 (94–100) 100 (–) 100 (–)
Serotype 14
IgG GMC 0.07 (0.03–0.13) 1.76 (1.38–2.24)*,** 9.43 (7.74–11.50)*** 0.41 (0.32–0.53) 1.01 (0.76–1.34)** 1.41 (1.15–1.72)*** 2.58 (1.91–3.47) 14.49 (11.58–18.13)** 11.99 (9.72–14.78)***
% IgG ≥0.35 g/ml 18 (4–32) 94 (88–99)*,** 100 (–)*** 48 (37–59) 85 (77–93)*,** 96 (92–100)*** 95 (90–100) 100 (–)** 100 (–)***
Serotype 18C
IgG GMC 0.06 (0.04–0.10) 0.19 (0.16–0.23)*,** 1.97 (1.65–2.34)*** 0.11 (0.09–0.14) 0.17 (0.13–0.22)*,** 0.24 (0.20–0.29)*** 2.64 (2.20–3.17) 3.25 (2.79–3.77) 2.93 (2.19–3.91)
%  IgG ≥0.35 g/ml 7 (0–17) 19 (10–27)* 100 (–)*** 10 (4–17) 20 (11–29)** 28 (18–39)*** 99 (96–100) 100 (–) 99 (96–100)
Serotype  19F
IgG GMC  0.56 (0.35–0.90) 0.94 (0.75–1.17)*,** 3.43 (2.84–4.13)*** 0.93 (0.75–1.14) 1.46 (1.09–1.96)** 1.83 (1.42–2.37)*** 1.99 (1.66–2.38) 6.09 (4.88–7.61)** 5.90 (4.87–7.14)***
% IgG ≥0.35 g/ml 61 (43–97) 84 (76–92)*,** 100 (–)*** 86 (78–94) 90 (83–97) 96 (92–100)*** 99 (96–100) 100 (–) 100 (–)
Serotype 23F
IgG GMC  0.05 (0.03–0.06) 0.21 (0.16–0.27)*,** 2.61 (2.11–3.22)*** 0.16 (0.13–0.20) 0.40 (0.30–0.55)** 0.57 (0.43–0.76)*** 0.73 (0.54–0.99) 4.88 (3.83–6.23)** 5.04 (4.04–6.28)***
% IgG ≥0.35 g/ml 0 (–) 28 (18–37)*,** 99 (96–100)*** 17 (9–25) 49 (38–60)** 59 (48–71)*** 63 (52–73) 99 (96–100)** 100 (–)***
* p-Values ≤ 0.05: 2-dose schedule vs. 2 + 1-dose schedule.
** p-Values ≤ 0.05: 2-dose schedule vs. controls.
*** p-Values ≤ 0.05: 2 + 1-dose schedule vs. controls.
5838 E. van Westen et al. / Vaccine 31 (2013) 5834– 5842
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t  12, 24 and 25 months of age. Signiﬁcant difference between 2 + 1-dose group and
.3. Opsonophagocytic antibody levels after different vaccination
chedules
Levels of opsonophagocytic antibodies were determined in a
andom selection of serum samples, with 18–40 subjects per group
Fig. 1). IgG GMCs of this subset were comparable to the IgG levels
f the immunogenicity arm of this study (data not shown).
In contrast to avidity indices, which did not show any differ-
nces, OPA GMTs in the 2 + 1-dose group were signiﬁcantly higher
ompared to the 2-dose group for all serotypes at the age of 12
onths (Fig. 3, Table 2 (for statistical analysis data)). Opsonophago-
ytic activity for the 2-dose group was signiﬁcantly higher than for
he control group, except for serotype 9V. Opsonophagocytic activ-
ty for control children at 12 months of age was low, except for
erotypes 9V and 14.
At 24 months of age, opsonophagocytic activity in the 2 + 1-dose
roup showed a signiﬁcant decrease for all serotypes compared to
MTs at 12 months of age. However, still signiﬁcantly higher OPA
MTs were found in the 2 + 1-dose group compared to the 2-dose
roup for 4 of the 7 serotypes (serotypes 4, 6B, 18C and 23F). In
he 2-dose group, OPA levels had increased for serotypes 9V and
9F and in the control group for serotypes 14, 19F and 23F (Fig. 3,
able 2 (for statistical analysis data)). This resulted in signiﬁcant
ifferences between the 2-dose group and the control group for
erotypes 4, 6B and 18C and between the 2 + 1-dose group and the
ontrol group for all serotypes except serotype 14.
At the age of 25 months, signiﬁcant differences between the 2-
ose and the 2 + 1-dose group were no longer present. Compared toose, 2 + 1-dose schedule or no vaccination (controls). Avidity indices were measured
se group are indicated by asterisk; p ≤ 0.05.
controls, the 2-dose and 2 + 1-dose group had signiﬁcantly higher
OPA GMTs for serotypes 6B and 19F, only the 2 + 1-dose group also
had signiﬁcantly higher OPA GMTs for serotype 23F.
One month after the booster dose OPA GMTs were signiﬁcantly
higher in children receiving the booster dose at 24 months of age
compared to the booster at 11 months.
Signiﬁcant correlations between OPA GMTs and IgG GMCs were
found in the 2-dose group and the 2 + 1-dose group for all time
points and serotypes, except for serotype 9V at 24 months of age
and serotype 19F at 25 months of age of the 2 + 1-dose group
(Table 2). In the control group, IgG GMCs increased after vaccina-
tion resulting in a signiﬁcant correlation for 4 out of 7 serotypes. In
case of low titers no correlation could be found (Table 2).
4. Discussion
In this study, we  evaluated the added value of functional anti-
body levels, avidity and opsonophagocytic activity, of IgG serum
antibodies after 2 primary doses and a booster dose at the age of 11
or 24 months. We  found that the differences between the 2 + 1-dose
group and the 2-dose group diminished with age and were most
pronounced in the opsonophagocytic activity and less pronounced
in IgG levels and avidity.
This is in line with data reported by Ekstrom et al., who showed
that avidity maturation occurred mainly after the primary series
and not shortly after a booster dose [28]. However Goldblatt et al.
also found some additional avidity maturation after the booster
dose [29]. A possible explanation for this difference could be that
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Table 2
Pneumococcal serotype-speciﬁc IgG antibody levels (GMCs; g/ml) and functional antibody titers (OPA GMTs;) with 95% CIs in infants after a 2-dose, 2 + 1-dose schedule or no vaccination until 24 months (controls); at the age
of  12 and 24 months, and at 25 months after an additional booster dose (n varied between 18 and 40 subjects per group).
12 Months 24 Months 25 Months
Controls 2-Dose 2 + 1-Dose Controls 2-Dose 2 + 1-Dose Controls 2-Dose 2 + 1-Dose
Serotype 4
IgG GMC 0.05 (0.03–0.08) 0.24 (0.20–0.30)*,** 2.60 (2.07–3.25)*** 0.06 (0.04–0.09) 0.13 (0.11–0.17)*,** 0.23 (0.18–0.28)*** 2.78 (1.89–4.09) 6.77 (5.24–8.74)*,** 3.82 (2.51–5.79)
OPA  GMT 4.0 (–) 10.0 (6.4–15.6)*,** 1222.1 (918.9–1625.3)*** 4.0 (–) 6.2 (4.4–8.7)*,** 14.2 (7.8–26.0)*** 2601.9 (1842.3–3674.5) 3758.2 (2885.1–4895.7) 2488.1 (1572.3–3937.3)
Correlation – 0.560 **** 0.582 **** – 0.411 **** 0.679 **** 0.627 **** 0.715 **** 0.739 ****
Serotype 6B
IgG GMC 0.08 (0.06–0.10) 0.23 (0.16–0.32)*,** 2.55 (1.71–3.79)*** 0.19 (0.14–0.27) 0.64 (0.39–1.05)*,** 1.26 (0.83–1.93)*** 0.54 (0.32–0.91) 6.36 (3.96–10.20)** 11.94 (6.87–20.73)***
OPA GMT 4.0 (–) 23.2 (10.8–49.9)*,** 1509.1 (956.6–2380.6)*** 10.0 (3.5–28.2) 59.5 (26.5–134.0)*,** 263.9 (125.4–555.3)*** 595.8 (197.4–1798.4) 2985.0 (1737.7–5127.7)** 5974.7 (3658.2–9758.3)***
Correlation – 0.600 **** 0.800 **** −0.138 0.774 **** 0.751 **** 0.366 0.783 **** 0.746 ****
Serotype 9V
IgG GMC 0.06 (0.04–0.08) 0.25 (0.19–0.32)*,** 2.22 (1.78–2.76)*** 0.12 (0.06–0.23) 0.28 (0.19–0.41)** 0.29 (0.23–0.37)*** 2.47 (1.83–3.34) 4.29 (3.41–5.39)** 3.11 (2.18–4.45)
OPA  GMT  12.6 (3.2–49.6) 12.1 (6.5–22.5)* 1570.3 (1205.2–2046.1)*** 17.6 (5.2–60.0) 46.1 (19.8–107.0) 93.6 (40.0–219.1)*** 3246.6 (2049.1–5144.0) 3067.0 (2220.1–4236.9) 3628.0 (2235.4–5888.3)
Correlation 0.301 0.505 **** 0.493 **** 0.275 0.469 **** 0.333 0.537 **** 0.602 **** 0.463 ****
Serotype 14
IgG GMC 0.08 (0.03–0.18) 1.71 (1.15–2.56)*,** 9.06 (6.80–12.08)*** 0.24 (0.13–0.43) 1.02 (0.68–1.55)** 1.28 (0.96–1.71)*** 2.89 (1.58–5.29) 18.29 (13.08–25.59)** 12.00 (7.77–18.53)***
OPA GMT 22.5 (5.3–95.5) 278.0 (153.3–504.3)*,** 2787.5 (2050.3–3789.8)*** 325.9 (81.2–1307.8) 356.9 (210.5–605.1) 434.1 (294.8–639.2) 6751.7 (3955.0–11526.1) 4876.8 (3473.3–6847.4) 3759.0 (2371.1–5959.5)
Correlation 0.524 **** 0.646 **** 0.478 **** 0.258 0.444 **** 0.514 **** 0.266 0.500 **** 0.530 ****
Serotype 18C
IgG GMC  0.06 (0.04–0.10) 0.20 (0.16–0.25)*,** 2.01 (1.57–2.59)*** 0.07 (0.05–0.10) 0.17 (0.12–0.23)** 0.24 (0.19–0.30)*** 2.84 (2.17–3.73) 3.70 (2.97–4.61) 2.96 (1.73–5.05)
OPA  GMT  4.0 (–) 17.1 (10.0–29.1)*,** 1551.4 (1159.3–2076.0)*** 4.00 (–) 12.2 (6.1–24.5)*,** 71.9 (35.4–146.2)*** 2722.6 (2043.9–3626.6) 3402.7 (2346.4–4934.5) 3783.3 (2031.5–7045.7)
Correlation – 0.414 **** 0.703 **** – 0.512 **** 0.512 **** 0.179 0.612 **** 0.823 ****
Serotype 19F
IgG GMC 0.44 (0.31–0.64) 0.95 (0.71–1.27)*,** 3.87 (3.05–4.91)*** 0.74 (0.45–1.21) 1.52 (0.96–2.41) 1.72 (1.23–2.42)*** 2.28 (1.70–3.06) 6.97 (4.95–9.81)** 6.04 (4.31–8.47)***
OPA GMT 4.0 (–) 16.2 (8.8–29.7)*,** 730.3 (470.3–1134.2)*** 12.9 (4.2–39.6) 47.8 (21.4–107.0) 103.7 (47.4–227.2)*** 365.9 (128.8–1039.5) 1934.9 (1195.8–3131.0)** 1771.7 (965.1–3252.6)***
Correlation – 0.333 **** 0.723 **** 0.348 0.629 **** 0.735 **** 0.527 **** 0.719 **** 0.388
Serotype  23F
IgG GMC  0.05 (0.04–0.06) 0.17 (0.13–0.23)*,** 2.96 (2.31–3.80)*** 0.12 (0.08–0.19) 0.43 (0.27–0.69)** 0.55 (0.38–0.78)*** 0.48 (0.27–0.84) 5.12 (3.72–7.05)** 5.75 (3.65–9.06)***
OPA GMT  4.0 (–) 34.5 (15.7–75.8)*,** 2658.1 (1953.8–3616.3)*** 22.1 (6.3–77.4) 95.3 (39.8–228.4)* 554.1 (298.–1029.0)*** 2300.6 (895.6–5909.8) 4883.6 (3276.0–7280.0) 7886.6 (4723.7–13167.3)***
Correlation – 0.516 **** 0.590 **** 0.284 0.589 **** 0.562 **** 0.528 **** 0.611 **** 0.774 ****
* p-Values ≤ 0.05: 2-dose schedule vs. 2 + 1-dose schedule.
** p-Values ≤ 0.05: 2-dose schedule vs. controls.
*** p-Values ≤ 0.05: 2 + 1-dose schedule vs. controls.
**** p-Values ≤ 0.05: Spearman correlation IgG GMCs vs. OPA GMTs.
5 accine 31 (2013) 5834– 5842
d
a
a
I
o
H
s
w
p
r
i
i
a
a
I
I
a
n
i
a
F
o
p
s
a840 E. van Westen et al. / V
ifferent vaccination schedules were used in both studies e.g. a 2, 4
nd 6 months and a 2, 3 and 4 months of age schedule, respectively.
The high correlation between IgG levels and opsonophagocytic
ctivity reported in our study could be explained by the fact that
gG concentrations are the most important factor contributing to
psonophagocytic activity, which was shown by Anttila et al. [30].
owever, OPA evaluation seems to be a more sensitive method
ince differences in OPA activity between both vaccination groups
ere shown which were not found when IgG levels were com-
ared. These discrepancies between IgG antibody levels and OPA
esponses could be caused by differences in avidity of vaccine-
nduced circulating IgG serotype-speciﬁc antibodies, but also by
nduction of speciﬁc antibodies of other isotypes like IgM and IgA,
s both have been reported to inﬂuence opsonic capacity of IgG
ntibodies [31–33]. Particularly after the ﬁrst dose of PCV, speciﬁc
gM antibodies have an important role in opsonophagocytosis [33].
n addition, serum antibodies to pneumococcal surface proteins
nd polyreactive antibodies induced by pneumococci present in
asopharynx may  have an impact on OPA responses. These antibod-
es are not induced by vaccination and may  increase with age [34],
s was shown for some serotypes in our control group. This could
ig. 3. Pneumococcal serotype-speciﬁc IgG antibody levels (GMCs; g/ml) and
psonophagocytic antibody titers (OPA GMTs; serum dilution able to kill 50% of
neumococci) with 95% CIs in infants after a 2-dose, 2 + 1-dose or no vaccination
chedule until 24 months (controls) at the age of 12 and 24 months, and at 25 months
fter an additional booster dose.
Fig. 3. (Continued )explain the high levels of functional antibodies against serotype
14 measured in the control group without vaccination. Carriage
data of this study showed that serotype 14, which is known to be
highly immunogenic [34], was  circulating during the study [13]. In
this trial, no differences between the 2-dose and 2 + 1-dose sched-
ule were found in the vaccine induced reduction of carriage after
vaccination at the age of 12 and 24 months, and the beneﬁt of a
booster dose at 11 months was  only temporarily seen at the age of
18 months [13].
The relationship between ELISA values and functional
opsonophagocytic activity may, however, vary per serotype [35].
Susceptibility to complement deposition is suggested as possible
cause of these inter-serotype differences in OPA [36]. Functional
OPA levels with a titer of ≥1:8 have previously been suggested as
additional correlate, however recently the WHO  recommended
that comparison of OPA titers should focus on serotype-speciﬁc
GMTs rather than the threshold functional titer ≥1:8 [6].
An important limitation of the opsonophagocytic killing assay in
general is that it is an in vitro assay, which is highly susceptible for
inter-laboratory variation and difﬁcult to standardize [37]. Com-
pared to ELISA, reproducibility and throughput are lower, despite
the used standardized multiplex OPA protocol with recommended
bacterial strains and HL-60 cell line [20]. Variation in the expres-
sion of capsular polysaccharides by the used pneumococcal strain
has been described as an inﬂuencing factor for serotype-speciﬁc
OPA responses [38]. Other disadvantages are that differentiation
of the HL-60 cell line is needed to get phagocytes but the number
of passages is limited for good differentiation and large volumes
of the serum samples are needed for this assay [39]. Despite these
disadvantages, OPA analysis is still recommended because of the
described added value of measuring functional antibodies.
In the 2 + 1-dose group rapid waning of (functional) antibodies
after the 11-month booster dose was seen. Rapid waning of (func-
tional) IgG antibodies after repeated vaccination has been reported
earlier in a Finnish study after a 3 + 1-dose schedule (PCV7 at 2, 4,
6 and 12 months) [21]. In this Finnish study, 95% of the children
had measurable OPA responses against serotype 19F and 23F one
month after the booster at 12 months, but only 33% and 52% of
the children still showed these OPA responses 1 year later, at 24
months of age, respectively [21]. Importantly, both our study and
the Finnish study were performed before national implementation
of PCV vaccinations, thus in a period without herd immunity. Vac-
cine serotypes were still circulating in the population and natural
boosting might have occurred.
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The limited difference in booster response after the PCV7 dose
t 24 months between the 2-dose and 2 + 1-dose group suggests
hat even a single booster dose at the age of 24 months, without
he early booster dose at 11 months, may  probably be sufﬁcient for
rotection. For some serotypes even a lower response was found in
he 2 + 1-dose group compared with the 2-dose group 1 month after
he vaccine dose given at 24 months of age. A case control study,
erformed in the USA during a period of vaccine shortage, showed
igh PCV7 effectiveness in infants who had received two primary
accine doses with or without a booster dose (98% and 96% vac-
ine efﬁcacy, respectively) though herd effects cannot be excluded
n protection [40]. Also in Australia, after nationwide implemen-
ation of a 3-dose schedule without a booster dose and without a
atch-up campaign, comparable vaccine effectiveness against vac-
ine serotype IPD was observed [11].
When waning immunity results in decreased clinical protec-
ion at later ages, a booster dose at an older age might be
eeded [41]. A booster dose given at 24 months resulted in higher
mmunogenicity responses than the response induced by a booster
ose administered at 11-months (2 + 1-dose versus 2-dose group).
onsidering the limited long-term beneﬁt of an early booster dose,
 later booster dose may  probably be advantageous for long-
erm protection [41], although this study did not asses antibody
ersistence after the 24 month booster dose. Signiﬁcant draw-
acks of a booster dose at 24 months are the potentially lower
ntibody-provided protection during the interval between the pri-
ary series and the booster dose at this young age and possibly an
dditional vaccination visit. The burden of IPD is highest between
he age of 6 and 18 months in most countries [1], but this problem
ight be reduced by a decrease of circulation of these serotypes.
ong-term surveillance data are needed to fully corroborate this
ossibility.
Recently, the WHO  recommended PCV administration in chil-
ren in a 3 + 0 or a 2 + 1 schedule [6] considering locally relevant
actors including epidemiology of pneumococcal disease, the likely
accine-serotype coverage, and the vaccination schedules of other
nfant vaccines. This is in line with our previous ﬁndings that a 2-
ose schedule induced a reduction in carriage and present ﬁndings
n timing of the booster dose.
PCV7 has been replaced by a ten-valent (PCV10) or thirteen-
alent (PCV13) pneumococcal conjugate vaccine [42–44]. Many
tudies have shown that the immunogenicity induced by PCV10
nd PCV13 against the 7 serotypes present in PCV7 is compara-
le to the response to PCV7 [45,46], therefore our ﬁndings in this
tudy are expected to be also applicable to the new conjugate
accines.
To summarize, at 12 months of age, the 2 + 1-dose group showed
igher antibody levels for most serotypes after a recent booster at
1 months compared to the 2-dose group, however at 25 months
f age after the booster at 24 months the difference between
oth groups had disappeared except for serotype 4, which was
ven higher in the 2-dose group (data Table 2). The kinetics of
psonophagocytic antibodies correlated well with the IgG antibody
evels for most serotypes, although differences between the 2-dose
nd the 2 + 1-dose group were more pronounced in functional activ-
ty as compared to the IgG levels especially at 24 months. Therefore,
e propose that OPA responses should be measured in addition to
neumococcal serotype speciﬁc IgG responses.
OPA GMTs were signiﬁcantly higher one month after the booster
ose in children receiving the booster at 24 months of age compared
o the effect of a booster given at 11 months of age. This must,
owever, be balanced against the risk of leaving children unboosted
etween the age of 11 and 24 months at a time when disease risk is
till high. Decision on the timing of a booster dose should be taken
ocally since they depend on local vaccine coverage and the indirect
erd effect in a well vaccinated population.
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